In addition, mean levels of serum TMEM166 were significantly lower in the control group (12.54 ± 3.74) than in patients with stroke after CEA (38.01 ± 10.01, p<0.05) (Fig. 1I). This evidence concerns the gene EVA1A and stroke disorder.